AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:09 2024-04-26 am EDT			5-day change	1st Jan Change
11,988 ^GBX	-0.32%		+9.52%	+13.09%

03:26pm	ASTRAZENECA : DZ Bank sticks Neutral	ZD
03:11pm	ASTRAZENECA : UBS keeps a Sell rating	ZD

ASTRAZENECA : UBS keeps a Sell rating

May 22, 2020 at 07:44 am EDT

UBS analyst reiterate his Sell rating on the stock. The target price remains unchanged at GBp 6000.

Latest news about AstraZeneca PLC

ASTRAZENECA : DZ Bank sticks Neutral	09:26am	ZD
ASTRAZENECA : UBS keeps a Sell rating	09:11am	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	08:11am	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	07:56am	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	07:43am	MT
Peel Hunt cuts ConvaTec to 'reduce'	04:34am	AN
THE FTSE 100 is on a roll	04:23am
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade	Apr. 25
FTSE 100 shakes off red-hot US inflation gauge	Apr. 25	AN
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
ASTRAZENECA : UBS maintains a Sell rating	Apr. 25	ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
The specter of stagflation rears its ugly head again	Apr. 25
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Sector Update: Health Care	Apr. 25	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Apr. 25	MT
ASTRAZENECA : Jefferies sticks Neutral	Apr. 25	ZD
ASTRAZENECA : JP Morgan remains its Buy rating	Apr. 25	ZD
FTSE 100 hits high on offer for Anglo American	Apr. 25	AN
Transcript : AstraZeneca PLC, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-28 - Roadshow - Day 1

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150.3 USD

Average target price

162.1 USD

Spread / Average Target

+7.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.09%	233B
ELI LILLY AND COMPANY	+26.37%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.72%	354B
MERCK & CO., INC.	+20.62%	331B
ABBVIE INC.	+2.11%	296B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.20%	144B
PFIZER, INC.	-11.52%	143B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : UBS keeps a Sell rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals